Recombinant AAV-directed gene therapy for type I glycogen storage diseases
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Glycogen storage disease (GSD) type Ia and Ib are disorders of impaired glucose homeostasis affecting the liver and kidney. GSD-Ib also affects neutrophils. Current dietary therapies cannot prevent long-term complications. In animal studies, recombinant adeno-associated virus (rAAV) vector-mediated gene therapy can correct or minimize multiple aspects of the disorders, offering hope for human gene therapy. AREAS COVERED: A summary of recent progress in rAAV-mediated gene therapy for GSD-I; strategies to improve rAAV-mediated gene delivery, transduction efficiency and immune avoidance; and vector refinements that improve expression. EXPERT OPINION: rAAV-mediated gene delivery to the liver can restore glucose homeostasis in preclinical models of GSD-I, but some long-term complications of the liver and kidney remain. Gene therapy for GSD-Ib is less advanced than for GSD-Ia and only transient correction of myeloid dysfunction has been achieved. A question remains as to whether a single rAAV vector can meet the expression efficiency and tropism required to treat all aspects of GSD-I, or if a multi-pronged approach is needed. An understanding of the strengths and weaknesses of rAAV vectors in the context of strategies to achieve efficient transduction of the liver, kidney and hematopoietic stem cells is required for treating GSD-I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490 · cited 3×
“For liver expression, rAAV2/1, rAAV2/7, rAAV2/8 and rAAV2/9 were best, but for kidney all AAV serotypes expressed low levels of luciferase [67].”
BackgroundMethodClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 2×
“[53] proposed that these conflicting observations can be explained if the host cell reconstructs larger AAV genomes through mechanisms of annealing and homologous recombination between overlapping deletion variants.”
BackgroundResultFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“2 Self-complementary rAAV vectors A major rate-limiting step in the life cycle of AAV is the need to convert the single-stranded (ss) DNA genome into doublestranded (ds) DNA prior to gene expression [44,45].”
BackgroundCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 2×
“Given the difference in immune reactivity seen between small and large animal models [73-77], it is important to replicate these results in the canine GSD-Ia model.”
BackgroundMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 1×
“The selfcomplementary AAV (scAAV) vectors, sometimes called dsAAV vectors, were developed to circumvent these mechanisms by packaging the gene of interest as a single inverted repeat that can spontaneouly reanneal into a dsDNA genome [46-48].”
BackgroundAAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 2×
“[85] showing an increased incidence of hepatocellular carcinoma in rAAV-infused mice, none of the GSD-I gene therapy studies that improved the metabolic defects have been designed to assess the development of HCA.”
BackgroundThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 1×
“Tyrosine-modified rAAV vectors, in which tyrosine residues on the surface of AAV capsid proteins are converted to phenylalanine residues by sitedirected mutagenesis, have markedly improved transduction efficiency [69-71].”
BackgroundMcCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547 · cited 5×
“The rAAV vectors are constructed by replacing the rep and cap genes with the promoter and gene of interest, leaving the ITRs as the only viral DNA sequences in the vectors.”
BackgroundInfluentialSelf-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 5×
“2 kb [48] and the primary compromise in using an scAAV is the 50% reduction in recombinant gene capacity to ~ 2.”
BackgroundInfluentialNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Samulski, R. J., Berns, K. I., Tan, M., & Muzyczka, N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2077 · Cited by 466
Integration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Grieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Myeloid Lineage Commitment from the Hematopoietic Stem Cell
Iwasaki, H., & Akashi, K. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.004 · Cited by 394 · cited 2×
“Neutrophils are terminally differentiated, short-lived, leukocytes that are replenished from the multipotent hematopoietic stem cells (HSCs) in the bone marrow [99,100].”
BackgroundThomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 1×
“This approach failed to normalize hypoglycemia or sustain the life of G6pc mice, presumably because slow uncoating of the AAV2 serotype delayed G6Pase-a expression [94] To address this, Sun et al.”
BackgroundAllocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · cited 2×
“Several studies suggested that packaging constraints for AAV are not as strict as previously reported [51,52].”
BackgroundResultCharacterization of Genome Integrity for Oversized Recombinant AAV Vector
Dong, B., Nakai, H., & Xiao, W. (2010) · Molecular Therapy · doi:10.1038/mt.2009.258 · Cited by 230 · cited 1×
“In contrast, three recent studies [53-55] reported that the AAV packaged genomes never exceed 5.”
ResultStructurally mapping the diverse phenotype of adeno-associated virus serotype 4
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M. (2006) · Journal of Virology · doi:10.1128/jvi.01536-06 · Cited by 205 · cited 1×
“In the last decade, 11 AAV serotypes and over 120 capsid variants have been categorized into six different phylogenetic clades [27-35] and the crystal structures of several AAV serotypes have been solved [36-40].”
BackgroundAAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191 · cited 2×
“The AAV capsid shell can be customized further using chimeric/mosaic capsids, site-directed or insertional mutagenesis, peptide display libraries and chemical conjugation to create epitopes that mediate binding to receptors on the cell types of interest [41-43].”
BackgroundAdeno-Associated Virus Integration: Virus versus Vector
Smith, R. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.55 · Cited by 178
Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb
Lai, Y., Yue, Y., & Duan, D. (2010) · Molecular Therapy · doi:10.1038/mt.2009.256 · Cited by 166
Markusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131 · cited 1×
“Tyrosine-modified rAAV vectors, in which tyrosine residues on the surface of AAV capsid proteins are converted to phenylalanine residues by sitedirected mutagenesis, have markedly improved transduction efficiency [69-71].”
Background
Cited by
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
“For viral RNA delivery, there has been a great deal of interest in the engineering of adeno‐associated viruses to carry nucleic acid cargoes [112].”
BackgroundDelivery of mRNA Therapeutics for the Treatment of Hepatic Diseases
Trepotec, Z., Lichtenegger, E., Plank, C., Aneja, M. K., & Rudolph, C. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.012 · Cited by 115
“A similar therapy based on adeno-associated virus vectors encoding G6P was applied to canine puppies, and it restored about 50% of normal G6P liver expression.(105) However, due to inherent risks from random insertions and a risk of cancerous effects, mRNA therapy would be a potential strategy to reverse the hepatic a…”
MethodGlycogen Storage Diseases: An Update
Gümüş, E., & Özen, H. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i25.3932 · Cited by 100
Genome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction
Mano, M., Ippodrino, R., Zentilin, L., Zacchigna, S., & Giacca, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503607112 · Cited by 39
Metadata
- Authors
- Chou, J. Y., & Mansfield, B. C.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2011-04-20
- Volume
- 11
- Issue
- 8
- Pages
- 1011-1024
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2105596705
- Cited by
- 27
- References
- 25
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.